Back
Axsome Therapeutics, Inc. (AXSM)
PharmaceuticalsAXSM · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$205.46
−0.02%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-3.68
ROE
-349.4%
Gross margin
92.6%
Debt/Equity
4.03x
Revenue growth
57.4%
Axsome Therapeutics, Inc. — company intelligence
Earnings surprises
Q2 2026$-0.99 vs $-0.86 est-14.9%
Q1 2026$-1.26 vs $-0.91 est-37.9%
Q4 2025$-0.56 vs $-0.68 est+18.0%
Q3 2025$-0.94 vs $-0.88 est-6.5%
Analyst consensus · 28 analysts
26 Buy2 Hold0 Sell
Updated Aug 16, 2026
Insider activity · 90 days
4 buys8 sellsnet -12,468 shares
TABUTEAU HERRIOTother 4,660 · Aug 6, 2026
TABUTEAU HERRIOTother 45,004 · Aug 5, 2026
TABUTEAU HERRIOTother 49,666 · Jul 1, 2026
Recent SEC filings
10-Q — Quarterly reportAug 10, 2026
8-K — Material event reportAug 10, 2026
4 — Insider transaction reportAug 7, 2026
Latest news
Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years — Benzinga · 1w ago
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today — Benzinga · 1w ago
Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $316 — Benzinga · 1w ago
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition — SeekingAlpha · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.